



August 09, 2023

To

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001

Tel: 022 - 2272 1233 /4

Fax: 022 - 22721919

Ref: Aragen Life Sciences Limited

Scrip Code: 973783

ISIN: INE483I07010

Sub: Publication of Extract of Financial Results in an English national daily newspaper

In compliance with Regulation 52 (8) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has, on Saturday, 05th August 2023, published in the 'Business Standard', an English national daily newspaper, the extract of the Financial Results of the Company for the quarter ended 30th June 2023. A copy of the newspaper publication is enclosed herewith.

Please take on your records.

For Aragen Life Sciences Limited

KASTURI | Digitally signed
by KASTURI
RAMAKRISHNA
Date: 2023.08.09
ISHNA | 14:37:30 +05'30'

Ramakrishna Kasturi

Company Secretary & Compliance Officer

CONTAINER CORPORATION OF INDIA LTD.
(A Public Limited Company)
B-Block, Plot No. 1, Naraina Company,
Sector 16, Connaught Place, New Delhi-110028.
Ph: 011-26359111 Fax: 011-26359112
Website: www.cci.co.in

NOTICE INVITING TENDER
CONTRACT NO. CE/EL/01/M/23/04/0001/001
Name of Work: Supply of cables and Electrical materials at MLSP/Parasagudi (Odisha) for 24 Months
Estimated Cost: Rs. 25,23,02,500 (inclusive of GST)
Period of the Contract: 24 Months (approx. divided in 6 Sections)
Earnest Money Deposit: Rs. 50,00,000/- through e-payment
Cost of Document: Rs. 1,000/- inclusive of all taxes and duties through e-payment
Tender Processing Fee: Rs. 2,00,000/- + 18% GST through account with a non-refundable
Date of Sale Online: From 07.08.2023 at 10:00 Hrs. to 28.08.2023 upto 18:00 Hrs.
Last Date & Time of submission of Tender: 28.08.2023 upto 18:00 Hrs. (E-Tendering Mode only)
Date & Time of opening of Tender: 30.08.2023 at 10:30 Hrs.
CONCORD reserves the right to reject all tenders without assigning any reasons therefor.
For complete details go to www.tenderindia.com, www.concordindia.com, www.tenderindia.com/CCI and Central Procurement Portal (CPP) only. Newspaper price advertisement shall not be issued for the same.
Sd/- General Manager/Ar/23-10

THE ASKA COOPERATIVE SUGAR INDUSTRIES LTD.
P.O. Nuagam (Aska) - 761111, Ganjam District, Odisha
Ph.No.06822-273464, email: askasugar@yahoo.co.in
Website: www.askasugar.com

TENDER CALL NOTICE
Letter No. Engr./211 Dt.02.08.2023
Sealed Tenders are invited from IBR licenced Contractors/Firm/Agencies/Organisations, etc for Supply of furnace wall tubes for 36 kg./cm²/40T/HR of MIL Make Boiler as per drawing. Quote separately for (a) Supply (b) Dismantling, Fabrication, Erection & Commissioning and mason works at the Aska Co-operative Sugar Industries Ltd, Nuagam, Aska. Interested tenders can get details & obtain tender form by download from our website - www.askasugar.com. The cost of tender paper is Rs 210/- non-refundable. Filled tender forms can be sent by Speed post/Registered post only, which should reach the office latest by dated 25/08/2023 by 5.00 PM. Secretary

Authum Investment & Infrastructure Limited
CIN No.: L51109MH1982PLC319008
Website: www.authum.com, Email: info@authum.com, Ph: 022-47472117
Registered Office: 707, Fakhra Centre, Free Press Journal Marg, Nurnam Point, Mumbai - 400 102.

EXTRACT OF STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023 (Rs. in Crores)

Sr No	Particulars	Standalone		Year Ended		Quarter Ended		Year Ended	
		30.06.2023	31.03.2023	30.06.2022	31.03.2022	30.06.2023	31.03.2023	30.06.2022	31.03.2022
1	Total Income from Operations (Net)	62.46	(117.22)	89.65	377.38	162.24	(80.77)	542.01	456.43
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	29.39	(154.34)	65.88	287.18	139.20	20.23	453.37	430.32
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	29.39	(154.34)	65.88	287.18	139.20	20.23	453.37	430.32
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	22.50	(134.28)	54.38	240.20	119.63	1,507.70	4,304.02	4,304.02
5	Total Comprehensive Income for the period (Comprising Profit/Loss) for the period (after tax) and Other Comprehensive Income	65.57	(147.80)	(88.41)	(130.29)	854.61	6,213.45	4,563.01	4,563.01
6	Equity Share Capital (face value of the share: ₹ 1 each)	16.98	16.98	16.98	16.98	16.98	16.98	16.98	16.98
7	Earnings Per Share (Face Value of ₹ 1/- Per Share) (for continuing and discontinued operations)	1.92	(7.91)	3.20	14.14	11.46	114.09	253.41	253.41
	1. Basic:	1.92	(7.91)	3.20	14.14	11.46	114.09	253.41	253.41
	2. Diluted:								

1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the website of the Stock exchange (www.bseindia.com) & on Company's website (www.authum.com)

By Order of Board
Sd/-
Authum Investment & Infrastructure Limited
Authum Dangle
Whole Time Director
DIN: 0652744

Date : 04th August, 2023
Place : Mumbai

Nava Limited
(formerly Nava Bharat Ventures Limited)
Regd. Office: 6-3-1109/1, Nava Bharat Chambers, Raj Bhavan Road, Hyderabad-500082
Corporate Identity No. L27101TG19ZPLC001546
Tel Nos. 040-2340353/040345999; e-Fax No. 080-6688 6121
Email ID: investorservices@navalimited.com; Website: www.navalimited.com

Extract of Standalone & Consolidated Unaudited Financial Results for the Quarter ended June 30, 2023 (Amount in lakhs of ₹ unless otherwise stated)

PARTICULARS	STANDALONE				CONSOLIDATED			
	Quarter ended	Quarter ended	Year ended	Quarter ended	Quarter ended	Year ended	Quarter ended	
	30.06.2023	31.03.2023	30.06.2022	31.03.2022	30.06.2023	31.03.2023	30.06.2022	31.03.2022
Total Income from Operations (net)	42,563.22	43,344.75	52,391.89	160,031.08	104,227.78	88,143.91	102,501.26	352,814.58
Net Profit/(Loss) for the period (before tax and exceptional items)	9,885.22	8,888.28	20,183.78	38,523.16	41,590.01	29,440.15	38,740.79	126,623.37
Net Profit/(Loss) for the period (before tax after exceptional items)	9,885.22	8,888.28	20,183.78	38,523.16	41,590.01	29,440.15	38,740.79	126,623.37
Net Profit/(Loss) for the period after tax (after exceptional items)	7,279.65	6,828.49	17,657.08	32,233.51	34,274.04	34,147.48	33,899.05	122,169.21
Total Comprehensive Income for the period	7,279.65	6,828.49	17,657.08	32,189.73	34,277.80	30,251.42	48,056.89	151,844.75
Equity Share Capital	-	-	2,903.27	-	-	-	-	2,903.27
Reserves (excluding Revaluation Reserves as shown in audited Balance Sheet of previous year)	-	-	350,436.88	-	-	-	-	5,99,639.38
Earnings per share (of ₹ 2/- each):								
Basic: (₹)	5.02	4.71	12.15	22.21	17.99	17.00	20.58	63.93
Diluted: (₹)	5.02	4.71	12.15	22.21	17.99	17.00	20.58	63.93

Notes:
The above is an extract of the detailed format of Quarterly unaudited and year ended audited financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The full format of the quarter ended unaudited financial results are available on the Stock Exchange Websites (www.bseindia.com) and on the Company's website (www.navalimited.com).
For NAVA LIMITED
DASHOK CHARIKMAN

Hyderabad
August 04, 2023

● METALS ● ENERGY ● MINING ● HEALTHCARE

MAGADH SUGAR & ERGOLYTD
Registered Office: P.O. Hargana, District Sitapur, Uttar Pradesh - 261 121
Phone (05862) 256220, Fax (05862) 256225, CIN: L15122UP2015PLC006932
Website: www.bifa-sugar.com, E-mail: bifasugar@bifa-sugar.com

Extract of the Unaudited Financial Results for the quarter ended 30 June 2023 (₹ in lakhs)

Sr. No.	Particulars	Three months ended		Year ended	Corresponding Three months ended
		30.06.2023	31.03.2023		
1	Total Income from Operations	30,071.35	95,341.98	24,569.10	14.11
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	2,077.94	7,709.07	14.11	14.11
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	2,077.94	7,709.07	14.11	14.11
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	1,553.95	5,026.15	7.88	7.88
5	Total Comprehensive Income for the period (Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	1,553.33	5,020.75	8.40	8.40
6	Equity Share Capital	1,409.16	1,409.16	1,409.16	1,409.16
7	Other Equity	62,527.50	-	-	-
8	Earnings Per share (of ₹ 10/- each) (in ₹):	11.03 *	35.67	0.06 *	0.06 *
	Basic & Diluted				

* Not annualised.
Notes:
The above is an extract of the detailed format of the Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results of the Company are available on the investor section of our website <http://www.bifasugar.com> and under Corporate Section of BSE Limited and National Stock Exchange of India Limited at <http://www.bseindia.com> and <http://www.nseindia.com> respectively.
For and on behalf of Board of Directors
MAGADH SUGAR & ERGOLYTD
Chandra Shekhar Nopany
Chairperson
Date : 4th August, 2023
Place : Kolkata
DIN - 00014587

ARAGEN LIFE SCIENCES LIMITED
(formerly known as Aragen Life Sciences Private Limited)
CIN: U74999TG2000PLC035826
Registered and Corporate Office: Plot 28A, IDA Nacharam, Hyderabad, Telangana-500076, India
Tel: +91 40 6692 9999 F: +91 40 6692 9900
Email id: compliances@aragen.com, website: www.aragen.com

Extract of standalone financial results for the quarter ended 30 June 2023 (amount in ₹ million)

S. No.	Particulars	Quarter ended		For the Year ended	
		30 June 2023	31 March 2023	30 June 2022	31 March 2022
1	Total Income from operations	3,419.28	3,879.90	3,782.81	15,599.65
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	497.19	968.11	713.83	3,349.12
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	497.19	968.11	713.83	3,349.12
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	373.14	744.30	536.50	2,519.19
5	Total Comprehensive Income for the period / Year (Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	563.61	983.08	238.76	2,278.54
6	Paid up Equity Share Capital (Face Value of ₹ 10/- each)	2,044.14	2,044.14	681.38	2,044.14
7	Reserves (excluding Revaluation Reserve)	-	-	1,106.27	1,106.27
8	Securities Premium Account	-	-	391.33	-
9	Net worth	12,768.09	12,172.92	10,671.31	12,172.92
10	Paid up Debt Capital	5,193.68	4,981.19	5,091.86	4,981.19
11	Outstanding Redeemable Preference Shares	N.A.	N.A.	N.A.	N.A.
12	Debt Equity Ratio	0.41	0.41	0.48	0.41
13	Earnings Per Share (EPS) (Face value of ₹ 10 each fully paid)*				
	Basic EPS (Rs)	1.85	3.68	2.66	12.47
	Diluted EPS (Rs)	1.82	3.63	2.62	12.31
14	Capital Redemption Reserve	-	-	3.36	-
15	Debture Redemption Reserve	200.00	200.00	200.00	200.00
16	Debt Service Coverage Ratio	3.63	4.30	4.22	3.40
17	Interest Service Coverage Ratio*	6.46	15.28	7.93	10.06

* Quarterly ended ratios are not annualised.
* EPS not annualised for the quarter ended.
Notes:
1. The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange(s) under Regulation 52 of the Listing Regulations. The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 03 August 2023. These Financial Results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013 read with the relevant rules there under and the other accounting principles generally accepted in India. Figures for the quarter ended 31 March 2023 represents the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the respective financial years.
2. For the other line items referred in Regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the stock exchange, BSE Limited, and can be accessed at www.bseindia.com. The full format of the quarterly/annual financial results including detailed notes thereon are available on the websites of the stock exchange-BSE Limited at www.bseindia.com and the Company at www.aragen.com.
3. During the year ended 31 March 2022, the Company had issued 2,000 rated, listed, redeemable, non-convertible Debentures (NCDs) of face value ₹ 1,000,000 each for a total amount of ₹ 2,000 million on a private placement basis. These NCDs have been listed on the Stock Exchange (BSE Limited) with effect from 14 February 2022. The NCDs are repayable at the end of 36 months from the date of allotment and carry an annual interest rate of 7.75% per annum due on 11 February of every year. In terms of regulation 54(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, these NCDs are secured by first charge on Property plant & equipment, movable CWP/IT including immovable property at Mallapur unit with minimum asset cover of 1.25x. During the quarter ended 31 March 2023, the Company had not received any complaints from the NCD holders and there has been no complaint pending for redressal at the beginning or at the end of the quarter. The equity shares of the Company are not listed on any Stock Exchange.
4. The statutory auditors of the Company ("BSR and Co") have carried out a limited review of the above unaudited standalone financial results for the quarter ended 30 June 2023 and have issued an unmodified review report. The review report of the Statutory auditors was filed with the BSE Limited and also is available on the Company's website.
5. During the year ended 31 March 2023, the Company has issued bonus equity shares of Rs. 10/- (Rupees Ten) each as fully paid-up Equity Shares in proportion of 2 (two) new fully paid-up Equity Shares of Rs. 10/- (Rupees Ten) for every 1 (One) existing fully paid-up Equity Shares of Rs. 10/- (Rupees Ten) each to the eligible shareholders on the record date, i.e., 27 January 2023. Consequently to this bonus issue, the earnings per share has also been adjusted for all the previous periods presented, in accordance with Ind AS 33. Earnings per share, Further the Authorized Share capital of the Company has increased from ₹ 1,420.00 million to ₹ 2,500.00 million and the number of authorized equity shares increased from 142,000 million to 250,000 million.
6. The Company has incorporated a wholly owned subsidiary in the name of Aragen Biologics Private Limited ("Biologics") on 21 June 2023, which is yet to commence its operations.
For Aragen Life Sciences Limited
Sd/-
Manmahesh Kantipudi
Whole-time Director & CEO
Date : 3rd August 2023
Place : Hyderabad
DIN: 05241166

Piramal Pharma Limited
CIN: U28299MH2020PLC358592
Regd. Office: G. Flr., Piramal Ananta, Agastya Corp. Park, Karam Juncion, LBS Marg, Kurla, Mumbai 400070
Tel No.: 022-38203000; Fax No.: 022-38203884; Email: shareholders@piramal.com; Website: www.piramal.com

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2023 Rupees (in crores)

Sr.	Particulars	Three months ended		Corresponding Three months ended	For the year ended
		30/06/2023	31/03/2023		
1	Revenue from Operations	1,748.85	2,163.58	1,481.99	7,081.55
2	Earnings before interest, depreciation, tax, share of profit of associates and joint venture and exceptional items for the period (EBITDA)	170.63	375.77	88.93	853.35
3	Net Profit / (Loss) for the period before tax, Exceptional and/or Extraordinary items)	(121.50)	87.11	(135.03)	(167.52)
4	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(121.50)	87.11	(135.03)	(174.48)
5	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(98.58)	50.11	(109.05)	(186.46)
6	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	(71.97)	67.39	(87.16)	(10.66)
7	Paid-up Equity Share Capital (Face Value ₹ 10/- each)	1,193.32	1,193.32	1,185.91	1,193.32
8	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	5,580.18
9	Earnings Per Share (Face value of ₹ 10/- each) (for continuing and discontinued operations) -				
	1. Basic:	(0.83)	0.42	(0.92)	(1.57)
	2. Diluted:	(0.83)	0.42	(0.92)	(1.57)

Notes:
1. Additional information of the Company on standalone basis is as follows:
Rupees (in crores)
Sr. Particulars Three months ended 30/06/2023 Three months ended 31/03/2023 Corresponding Three months ended 30/06/2022 For the year ended 31/03/2023
(Unaudited) (Refer Note 3) (Unaudited) (Audited)
1. Total Income from continuing operations 873.11, 1,117.46, 853.08, 3,784.29
2. Total Income from discontinued operation - - - -
3. Profit / (Loss) before tax from continuing operations (40.90), 65.64, (24.60), 123.69
4. Profit / (Loss) before tax from discontinued operations - - - -
5. Profit / (Loss) after tax from continuing operations (33.36), -41.70, (17.12), 69.50
6. Profit / (Loss) after tax from discontinued operations - - - -
2. The above is an extract of the detailed format of Standalone and Consolidated Financial Results for the three months ended June 30, 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of Financial Results for the three months ended June 30, 2023 are available on the Stock Exchange websites (www.bseindia.com) and (www.nseindia.com) and the Company's website (www.piramal.com).
3. The figures for the last quarter of the previous financial year are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of third quarter of the previous financial year which were subjected to limited review by statutory auditors.
For Piramal Pharma Limited
Nandini Piramal
Chairperson
Date : August 3, 2023
DIN: 00286092